VAXCYTE, INC. Stock-Based Compensation
VAXCYTE, INC. (PCVX) reported Stock-Based Compensation of $79.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- VAXCYTE, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $41.24M, a 11.68% increase year-over-year.
- VAXCYTE, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $37.96M, a 24.00% increase year-over-year.
- VAXCYTE, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $36.00M, a 47.71% increase year-over-year.
- VAXCYTE, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $35.31M, a 66.03% increase year-over-year.
- VAXCYTE, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $138.84M, a 63.69% increase from fiscal 2024.
- VAXCYTE, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $84.82M, a 73.96% increase from fiscal 2023.
- VAXCYTE, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $48.76M, a 106.17% increase from fiscal 2022.
- VAXCYTE, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $23.65M, a 120.43% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $79.20M 10-Q · filed 2026-08-05 | $115.20M derived: sum of 3 quarters · filed 2026-08-05 | $150.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $37.96M 10-Q · filed 2026-05-06 | $73.96M derived: sum of 2 quarters · filed 2026-05-06 | $109.27M derived: sum of 3 quarters · filed 2026-05-06 | $146.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $71.30M derived: sum of 2 quarters · filed 2026-02-24 | $108.23M derived: sum of 3 quarters · filed 2026-08-05 | $138.84M 10-K · filed 2026-02-24 |
| 2025-09-30 | $35.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $72.23M derived: sum of 2 quarters · filed 2026-08-05 | $102.85M 10-Q · filed 2025-11-04 | $127.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $36.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $67.54M 10-Q · filed 2026-08-05 | $91.91M derived: sum of 3 quarters · filed 2026-08-05 | $113.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $30.61M 10-Q · filed 2026-05-06 | $54.98M derived: sum of 2 quarters · filed 2026-05-06 | $76.25M derived: sum of 3 quarters · filed 2026-05-06 | $97.81M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $24.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $45.63M derived: sum of 2 quarters · filed 2026-02-24 | $67.19M derived: sum of 3 quarters · filed 2026-02-24 | $84.82M 10-K · filed 2026-02-24 |
| 2024-09-30 | $21.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $42.82M derived: sum of 2 quarters · filed 2025-11-04 | $60.45M 10-Q · filed 2025-11-04 | $73.80M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $21.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $39.19M 10-Q · filed 2025-08-06 | $52.53M derived: sum of 3 quarters · filed 2026-02-24 | $65.75M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $17.63M 10-Q · filed 2025-05-07 | $30.98M derived: sum of 2 quarters · filed 2026-02-24 | $44.20M derived: sum of 3 quarters · filed 2026-02-24 | $56.74M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $13.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $26.57M derived: sum of 2 quarters · filed 2026-02-24 | $39.11M derived: sum of 3 quarters · filed 2026-02-24 | $48.76M 10-K · filed 2026-02-24 |
| 2023-09-30 | $13.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $25.76M derived: sum of 2 quarters · filed 2024-11-05 | $35.41M 10-Q · filed 2024-11-05 | $42.42M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $12.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $22.19M 10-Q · filed 2024-08-06 | $29.20M derived: sum of 3 quarters · filed 2025-02-25 | $35.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $9.65M 10-Q · filed 2024-05-08 | $16.66M derived: sum of 2 quarters · filed 2025-02-25 | $23.30M derived: sum of 3 quarters · filed 2025-02-25 | $29.20M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $13.66M derived: sum of 2 quarters · filed 2025-02-25 | $19.55M derived: sum of 3 quarters · filed 2025-02-25 | $23.65M 10-K · filed 2025-02-25 |
| 2022-09-30 | $6.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $12.54M derived: sum of 2 quarters · filed 2023-11-06 | $16.64M 10-Q · filed 2023-11-06 | $19.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $5.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.99M 10-Q · filed 2023-08-08 | $13.15M derived: sum of 3 quarters · filed 2024-02-27 | $16.09M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $4.10M 10-Q · filed 2023-05-08 | $7.26M derived: sum of 2 quarters · filed 2024-02-27 | $10.19M derived: sum of 3 quarters · filed 2024-02-27 | $12.96M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $6.09M derived: sum of 2 quarters · filed 2024-02-27 | $8.86M derived: sum of 3 quarters · filed 2024-02-27 | $10.73M 10-K · filed 2024-02-27 |
| 2021-09-30 | $2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $5.71M derived: sum of 2 quarters · filed 2022-11-07 | $7.57M 10-Q · filed 2022-11-07 | $9.51M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $4.63M 10-Q · filed 2022-08-08 | $6.57M derived: sum of 3 quarters · filed 2023-02-27 | $8.41M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.86M 10-Q · filed 2022-05-09 | $3.80M derived: sum of 2 quarters · filed 2023-02-27 | $5.64M derived: sum of 3 quarters · filed 2023-02-27 | $6.93M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $3.77M derived: sum of 2 quarters · filed 2023-02-27 | $5.06M derived: sum of 3 quarters · filed 2023-02-27 | $5.43M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $3.13M derived: sum of 2 quarters · filed 2021-11-10 | $3.50M 10-Q · filed 2021-11-10 | $3.87M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.66M 10-Q · filed 2021-08-11 | $2.04M derived: sum of 3 quarters · filed 2022-02-28 | $2.30M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $372.00K 10-Q · filed 2021-05-11 | $747.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.01M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $640.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.19M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $265.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $810.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $545.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $749.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |